Clinical Trial: Microbiology of Severe Acute Tonsillitis, Peritonsillar Cellulitis, and Infectious Mononucleosis

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Observational

Official Title: Mikrobiologi Ved svær Akut Tonsillit, peritonsillær Phlegmone og infektiøs Mononukleose

Brief Summary: Prospective, observational study of the microbiology of patients referred to a tertiary care center with severe acute tonsillitis, peritonsillar cellulitis, or infectious mononucleosis.

Detailed Summary:

Patients referred to tertiary care centers with acute throat infections are most often treated with antibiotics. However, very little is know concerning the prevalent pathogens in patients with acute throat infections without abscess formation. Evidence suggests that Fusobacterium necrophorum plays an important role in complications of acute tonsillitis (e.g. peritonsillar abscess), but also uncomplicated acute tonsillitis.

This study aims to explore the throat microbiology of patients with severe acute tonsillitis, peritonsillar cellulitis, or infectious mononucleosis with a special attention to a possible role of Fusobacterium necrophorum.

Sponsor: Tejs Ehlers Klug

Current Primary Outcome: Prevalence of Fusobacterium necrophorum in throat swab cultures [ Time Frame: At acute consultation (day 0) ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

• Number of participants with recurrent throat infections (questionnaire) [ Time Frame: Six months after acute consultation ]
• Number of participants without eradication of throat pathogens (throat cultures) [ Time Frame: 14-28 days after acute consultation ]
  "Throat pathogens": Fusobacterium necrophorum, Beta-hemolytical streptococci, A. hemolyticum
• Number of participants with complications of severe acute tonsillitis, peritonsillar cellulitis, and infectious mononucleosis [ Time Frame: 14-28 days after acute consultation ]
  "Complications": admission, abscess Development, change of antibiotic treatment
• Prevalence of anti-Fusobacterium necrophorum antibody Development (two-fold or higher increase in antibody level) (blood samples) [ Time Frame: In acute and convalescent sera (day 0 and 14-28) ]
  Comparison of the prevalence of antibody Development (two-fold or higher increase in antibody level) between patients with recovery of Fusobacterium necrophorum in throat swabs versus patients without recovery of Fusobacterium necrophorum in throat swabs

Original Secondary Outcome: Same as current

Information By: Aarhus University Hospital

Dates:
Date Received: March 14, 2016
Date Started: June 2016
Date Completion: December 2021
Last Updated: March 21, 2016
Last Verified: March 2016